BioWorld

Feb. 14, 2008

Avastin Improves PFS Again in Phase III Breast Cancer Trial

A Phase III trial of Avastin (bevacizumab) in breast cancer met its primary endpoint of improving progression-free survival (PFS), but analysts remained split on whether the new data would be enough to gain FDA approval. (BioWorld Today) Read More

Inspire's Denufosol Starts 2nd Phase III Study in Cystic Fibrosis

Vertex Offerings Expected to Raise up to $405.8M

Panel: Good Communication Cuts Dangers of Shareholder Activism

Genzyme Barely Misses; Posts Strong Fourth-Quarter Sales

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...